Gertjan Wolbink

Gertjan Wolbink publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Gertjan Wolbink sits on this spectrum.

Gertjan Wolbink D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Gertjan Wolbink sits on this spectrum.

Best Publications

• Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

  Eli A Stahl;Soumya Raychaudhuri;Soumya Raychaudhuri;Elaine F Remmers;Gang Xie

  1563
  Citations

• Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

  Geertje M Bartelds;Carla A Wijbrandts;Michael T Nurmohamed;Steven Stapel

  747
  Citations

• Common variants at CD40 and other loci confer risk of rheumatoid arthritis

  Soumya Raychaudhuri;Soumya Raychaudhuri;Soumya Raychaudhuri;Elaine F Remmers;Annette T Lee;Rachel Hackett

  645
  Citations

• Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

  Gerrit Jan Wolbink;Marijn Vis;Willem Lems;Alexandre E. Voskuyl

  636
  Citations

• Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.

  J Pijpe;van Gustaaf Imhoff;Frederik Spijkervet;Jan Roodenburg

  611
  Citations

• C-Reactive Protein Colocalizes With Complement in Human Hearts During Acute Myocardial Infarction

  W.K. Lagrand;H.W.M. Niessen;G.J. Wolbink;L.H. Jaspars

  579
  Citations

• Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.

  Pauline A. van Schouwenburg;Theo Rispens;Gerrit Jan Wolbink

  519
  Citations

• Genetic variants at CD28, PRDM1, and CD2/CD58 are associated with rheumatoid arthritis risk

  Soumya Raychaudhuri;Soumya Raychaudhuri;Soumya Raychaudhuri;Brian P Thomson;Elaine F Remmers;Stephen Eyre

  414
  Citations

• Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity.

  Mads Delbo Larsen;Erik L. de Graaf;Myrthe E. Sonneveld;H. Rosina Plomp

  384
  Citations

• Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study

  W H Bos;G J Wolbink;M Boers;G J Tijhuis

  348
  Citations

• CRP-MEDIATED ACTIVATION OF COMPLEMENT IN VIVO : ASSESSMENT BY MEASURING CIRCULATING COMPLEMENT-C-REACTIVE PROTEIN COMPLEXES

  G. J. Wolbink;M. C. Brouwer;S. Buysmann;I. J. M. Ten Berge

  317
  Citations

• Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

  Geertje M Bartelds;Carla A Wijbrandts;Michael T Nurmohamed;Steven O Stapel

  306
  Citations

• Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.

  R. L. West;Z. Zelinkova;G. J. Wolbink;E. J. Kuipers

  288
  Citations

• Development of the anti–citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis

  Lotte A. van de Stadt;Margret H. M. T. de Koning;Rob J. van de Stadt;Gertjan Wolbink

  285
  Citations

• Dealing with immunogenicity of biologicals: assessment and clinical relevance

  Gerrit J Wolbink;Lucien A Aarden;B A C Dijkmans

  274
  Citations

• Key findings towards optimising adalimumab treatment: the concentration–effect curve

  Mieke F Pouw;Charlotte L Krieckaert;Michael T Nurmohamed;Desiree van der Kleij

  261
  Citations

• Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurement

  Lucien Aarden;Sigrid R Ruuls;Gertjan Wolbink

  260
  Citations

• A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells

  C.Erik Hack;Gert-Jan Wolbink;Caspar Schalkwijk;Han Speijer

  252
  Citations

• Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

  C J van der Laken;A E Voskuyl;J C Roos;M Stigter van Walsum

  251
  Citations

• The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

  Anna Jamnitski;Geertje M Bartelds;Michael T Nurmohamed;Pauline A van Schouwenburg

  250
  Citations